
    
      This is a multicenter study of pegloticase in adult participants with uncontrolled gout who
      have undergone kidney transplantation.

      The study design will include: 1) a Screening Period, lasting up to 35 days; 2) a 24-week
      treatment period which includes an End-of-Study (Week 24) /Early Termination Visit; 3) a
      safety follow-up phone/email Visit 30 days after the last infusion; and 4) a 3 month
      post-treatment follow up visit.
    
  